Immune response to liver perfusion therapy for eye melanoma
Part of Cancer, Eyes & vision clinical trials.
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have uveal melanoma (an eye cancer) that has spread to the liver.
- You are physically well enough to have a daily activity score of 0 or 1 (fully active to slightly restricted).
- You have at least one liver tumor that is 1 cm or larger and can be biopsied.
- Your blood tests show adequate kidney and liver function and normal blood cell counts.
- You are not pregnant, breastfeeding, or taking medications that increase bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This Phase 1 trial tests a treatment using a patient’s own immune cells (TILs) plus a brief period of chemotherapy to help the immune system fight melanoma that has spread mainly to the liver. It may be an option if your melanoma has progressed after prior medicines and you have liver lesions that can be removed to make the cells.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This early-phase study tests whether melphalan can be used to reduce (shrink) a type of eye cancer called choroidal melanoma before additional treatment. It may help by controlling tumor size while doctors closely monitor the eye and outcomes.
This trial tests if adding another drug called IL-2 to tebentafusp can help stop cancer from growing in people with advanced melanoma that started in the eye (uveal melanoma). It is for those whose cancer got worse while on tebentafusp alone.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.